Ovarian Mass in a Patient with Prior Breast Cancer: Staging vs. Histologic Assignment
A 58-year-old woman with a history of ER-positive breast cancer treated with mastectomy and adjuvant endocrine therapy 6 years ago presents with a 9 cm complex right adnexal mass, ascites, and a CA-125 of 640 U/mL. She undergoes primary cytoreductive surgery. The final pathology describes a high-grade serous carcinoma involving both ovaries, omentum, and a 1.5 cm implant on the sigmoid serosa; the appendix is negative. Immunohistochemistry shows the tumor is PAX8 positive, GATA3 negative, ER positive, and WT1 positive. The abstractor must assign the primary site and stage for the registry.
1. How should the abstractor determine whether this is a new primary ovarian cancer versus a metastasis from the prior breast cancer, and what role do the IHC markers and clinical history play?
Read the worked answer
The key judgment is that site assignment is not decided by history alone but by the weight of evidence supporting a new primary. A prior breast cancer 6 years earlier does not preclude a new primary ovarian malignancy, and the registry rules require abstracting a new primary when the clinical and pathologic evidence supports it.
Reasoning steps:
- Morphology and immunophenotype: High-grade serous histology with PAX8+, WT1+, GATA3−, ER+ is classic for a Müllerian (ovarian/tubal/peritoneal) primary. Breast carcinoma metastatic to the ovary would typically be GATA3+ and WT1−/PAX8− (though PAX8 can be focal in some breast cancers).
- Distribution: Bilateral ovarian involvement with omental and peritoneal implants is the expected spread pattern of advanced ovarian carcinoma; breast metastases to the ovary are usually unilateral and rarely produce diffuse peritoneal carcinomatosis as the dominant pattern.
- Timing: A 6-year interval with no intervening recurrence makes a late breast metastasis less likely, though not impossible.
- Conclusion: Abstract as a new primary ovarian (high-grade serous) carcinoma. Document the prior breast primary as a separate history and do not link the two as one sequence unless the physician explicitly states metastasis.
2. Given the operative and pathology findings, assign the FIGO stage and explain which findings drive the assignment.
Read the worked answer
Stage assignment requires translating each finding into the FIGO/TNM criteria.
Findings:
- Both ovaries involved → within stage II/III spectrum depending on extra-ovarian spread.
- Omental involvement → stage III (microscopic or macroscopic peritoneal metastasis outside the pelvis).
- Sigmoid serosal implant (1.5 cm) → stage III (peritoneal metastasis beyond the pelvis).
- Ascites with positive cytology (implied by the clinical picture; confirm on report) → does not by itself upgrade beyond III but supports peritoneal spread.
- No parenchymal liver/spleen, no extra-abdominal disease described → not stage IV.
Because peritoneal metastases are macroscopic (>2 cm versus ≤2 cm matters for IIIA/IIIB/IIIC only in older schemas; current FIGO uses IIIA1/IIIB/IIIC distinctions), the abstractor should confirm the size and whether nodes are involved. With gross omental and serosal implants and no nodal data, the correct assignment is FIGO stage IIIB (macroscopic peritoneal metastasis beyond the pelvis ≤2 cm) or IIIC if nodes are positive or implants exceed 2 cm. The abstractor must verify node status and implant size before finalizing; if nodes are negative and implants are ≤2 cm, IIIB; if >2 cm or node-positive, IIIC. Document the basis explicitly in the abstract.
3. What data-quality checks should the abstractor perform before finalizing this case, and what common errors should be avoided?
Read the worked answer
Data-quality checks:
- Primary site consistency: Ensure the primary site code matches the histology and IHC (ovary, high-grade serous), not breast. Verify the prior breast primary is recorded separately with its own date of diagnosis.
- Stage–treatment concordance: Confirm that the documented stage is consistent with the surgery performed (cytoreduction) and that any neoadjuvant versus adjuvant sequencing is captured correctly.
- Date fields: Date of diagnosis should reflect the first positive pathologic confirmation or the clinical diagnosis date per registry rules, not the date of the prior breast cancer.
- Completeness: Capture CA-125, ascites, cytology, nodal status, residual disease after cytoreduction, and IHC as supporting text fields.
Common errors to avoid:
- Misassigning the case as metastatic breast cancer based on history alone.
- Recording stage IV because of ascites (ascites alone is not stage IV).
- Failing to record the second primary as a distinct record.
- Omitting residual disease status, which affects prognosis and treatment reporting.